Co-Authors
This is a "connection" page, showing publications co-authored by DANIEL M HALPERIN and BETH CHASEN.
Connection Strength
0.176
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29; 403(10446):2807-2817.
Score: 0.060
-
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Apr 01; 31(4).
Score: 0.059
-
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 09 07; 115(9):1001-1010.
Score: 0.057